SEC filing: Statement of changes in beneficial ownership of securities Share on Facebook Share on Facebook Share on LinkedIn Share on LinkedIn Share on X Share on X Share on Pinterest Share on Pinterest Share via email Share via email
investor nutraceuticals medicine press clippings International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to make Article excerpt Read more
heltzen investor press clippings Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel) Read more
press release investor nutraceuticals medicine eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion Los Angeles, CA -- December 11, 2025 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a... Read more